(Albany, US) September 21, 2026 – DelveInsight’s, “Dermatomyositis Pipeline Insight 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Dermatomyositis pipeline landscape. It covers the Dermatomyositis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dermatomyositis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Dermatomyositis Pipeline? @ https://www.delveinsight.com/sample-request/dermatomyositis-pipeline-insight

Key Takeaways from the Dermatomyositis Pipeline Report

• On Septemer 17, 2026- Cabaletta Bio conducted a phase 1/2 study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.
• On September 15, 2026- Priovant Therapeutics, Inc. initiated a phase 3, multicenter, randomized, placebo-controlled, double-blind study of treatment with brepocitinib (TYK2/JAK1 inhibitor) in adults with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of two dose levels of brepocitinib in comparison to placebo, as measured by differences in the Total Improvement Score (TIS). After 52 weeks of double-blind treatment, participants have the option to continue therapy in a 52 week open-label extension phase where all participants will receive brepocitinib.
• On September 15, 2026- Pfizer highlighted a phase 3 study is to understand how the study medicine PF-06823859 (dazukibart) works in people with idiopathic inflammatory myopathies (DM and PM). These disorders cause inflammation that weakens the muscles that are important for movement and may also cause skin rash in people with DM.
• On September 02, 2026- Fate Therapeutics conducted a Phase 1/2, open-label trial designed to evaluate the safety, pharmacokinetics (PK), anti-B-cell activity, and clinical activity of FT839 in participants with moderate-to-severe ANCA-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and systemic sclerosis (SSc).
• DelveInsight’s Dermatomyositis Pipeline report depicts a robust space with 120+ active players working to develop 125+ pipeline therapies for Dermatomyositis treatment.
• The leading Dermatomyositis Companies such as Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals, and others.
• Promising Dermatomyositis Pipeline Therapies such as FT839, Infliximab, Belimumab, Daxdilimab, Descartes-08, EFG PH20 SC, PF-06823859 and others.

Want to know which companies are leading innovation in Dermatomyositis? @ Dermatomyositis Clinical Trials Assessment

The Dermatomyositis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Dermatomyositis Pipeline Report also highlights the unmet needs with respect to the Dermatomyositis.

Dermatomyositis Overview

Dermatomyositis is a rare inflammatory autoimmune disease characterized by muscle inflammation and distinctive skin manifestations. It can cause progressive muscle weakness, particularly in the shoulders, hips, neck, and trunk, along with symptoms such as a heliotrope rash, Gottron’s papules, and other characteristic skin changes. The condition may also affect the lungs, joints, and other organs, and some patients may have an increased risk of malignancy. Diagnosis typically involves clinical evaluation, muscle enzyme testing, autoantibody assessment, imaging, electromyography, and, when necessary, muscle or skin biopsy. Treatment generally focuses on controlling inflammation and improving muscle function through corticosteroids, immunosuppressive or immunomodulatory therapies, physical rehabilitation, and management of associated complications.

Dermatomyositis Emerging Drugs Profile

• EFG PH20: argenx

Efgartigimod is designed as a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn). Efgartigimod is being evaluated for the treatment of patients with severe autoimmune diseases with confirmed presence of pathogenic immunoglobulin G, IgG autoantibodies, where a severe unmet medical need exists. A Phase II/III study (NCT05523167) is evaluating the efficacy and safety of efgartigimod PH20 SC compared to placebo in adults with active IIMs, including DM, immune-mediated necrotizing myopathy (IMNM), polymyositis (PM), and antisynthetase syndrome. The primary endpoint is treatment response measured by Total Improvement Score (TIS). Another study (NCT05979441) is assessing the long-term safety and efficacy of subcutaneous efgartigimod in adults with IIMs. The drug is currently in Phase III stage of development to treat Dermatomyositis.

• KZR-616: Kezar Life Sciences

KZR-616 offers a novel approach to harmonizing the immune system via selective immunoproteasome inhibition. Playing a critical role in the body’s immune system, the immunoproteasome is abundantly expressed in immune cells and acts as a master regulator of multiple cellular functions. By selectively inhibiting the immunoproteasome, KZR-616 has the potential to affect multiple drivers of immune-mediated diseases.

If you’re tracking ongoing Dermatomyositis Clinical trials, this press release is a must-read @ Dermatomyositis Treatment Drugs

The Dermatomyositis Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Dermatomyositis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dermatomyositis Treatment.
• Dermatomyositis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dermatomyositis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dermatomyositis market.

Dermatomyositis Companies

Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals, and others.

Dermatomyositis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Dermatomyositis Products have been categorized under various Molecule types such as,

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Dermatomyositis Pipeline Report covers it all @ Dermatomyositis Market Drivers and Barriers, and Future Perspectives

Scope of the Dermatomyositis Pipeline Report

• Coverage- Global
• Dermatomyositis Companies- Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals, and others.
• Promising Dermatomyositis Pipeline Therapies- FT839, Infliximab, Belimumab, Daxdilimab, Descartes-08, EFG PH20 SC, PF-06823859 and others.
• Dermatomyositis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Dermatomyositis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Dermatomyositis Treatment landscape in this detailed analysis @ Dermatomyositis Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Dermatomyositis Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Dermatomyositis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. EFG PH20: argenx
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. KZR-616: Kezar Life Sciences
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Dermatomyositis Key Companies
20. Dermatomyositis Key Products
21. Dermatomyositis Unmet Needs
22. Dermatomyositis Market Drivers and Barriers
23. Dermatomyositis Future Perspectives and Conclusion
24. Dermatomyositis Analyst Views
25. Dermatomyositis Key Companies
26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/dermatomyositis-pipeline-insight